Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 25;22(1):730.
doi: 10.1186/s12884-022-05043-w.

Use of convalescent plasma in pregnant women with early stage COVID-19 infection in a tertiary care hospital in Dubai, February to March 2021: a case series study

Affiliations

Use of convalescent plasma in pregnant women with early stage COVID-19 infection in a tertiary care hospital in Dubai, February to March 2021: a case series study

Heba Adan et al. BMC Pregnancy Childbirth. .

Abstract

Background: The use of COVID-19 convalescent plasma (CCP) for the treatment of SARS-CoV-2 infection in pregnancy is intriguing in view of its safety profile in pregnancy and historical precedence of the use of plasma for other viral illnesses. This study aimed to evaluate the use of CCP in pregnant women with early COVID-19 infection.

Methods: This is a retrospective case series study. We have included seven pregnant women admitted with early COVID-19 infection to a tertiary care hospital, Latifa Maternity Hospital in Dubai, United Arab Emirates between 12 February and 04 March 2021 and who consented to receive COVID-19 convalescent plasma as part of their treatment plan. Main outcomes measured were clinical and radiological features, laboratory tests, WHO clinical progression scale pre and post treatment, and maternal, fetal outcomes. COVID-19 clinical severity was classified according to the NIH guidelines for criteria of SARS-CoV-2. For the radiological features, a modified chest X-ray scoring system was used where each lung was divided into 6 zones (3 on each side upper, middle, and lower). Opacities were classified into reticular, ground glass, patchy and dense consolidations patterns.

Results: Seven pregnant women with early COVID-19 were enrolled in this study, their mean age was 28 years (SD 3.6). Four had comorbidities: 2 with diabetes, 1 with asthma, and 1 was obese. Five patients were admitted with a WHO clinical progression score of 4 (hospitalized; with no oxygen therapy) and 2 with a score of 5 (hospitalized; oxygen by mask/nasal prongs). Upon follow up on day 10, 6 patients had a WHO score of 1 or 2 (asymptomatic/mild symptoms) indicating clinical recovery. Adverse reactions were reported in 2 patients, one reported a mild skin rash, and another developed transfusion related circulatory overload. All patients were discharged alive.

Conclusion: CCP seems to be a promising modality of treating COVID-19 infected pregnant women. However, further studies are needed to ascertain the efficacy of CCP in preventing progressive disease in the management of COVID-19 infection in pregnant women.

Keywords: COVID-19; Convalescent plasma; Dubai; Pregnancy; SARS-Cov-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

Fig. 1
Fig. 1
A Patient 1 - CXR on admission. B Patient 1 - CXR on discharge
Fig. 2
Fig. 2
A Patient 2 - Chest X-ray on admission
Fig. 3
Fig. 3
A Patient 3 - CXR on admission. B Patient 3 - Follow up CXR. C Patient 3 - CXR on discharge
Fig. 4
Fig. 4
A Patient 4 - CXR on admission. B Patient 4 - Follow up CXR. C Patient 4 - CXR on discharge
Fig. 5
Fig. 5
A Patient 5 - CXR on admission. B Patient 5 -CXR on discharge
Fig. 6
Fig. 6
A Patient 6 - CXR on admission. B Patient 6 - CXR on discharge
Fig. 7
Fig. 7
A Patient 7 - CXR on admission. B Patient 7 - CXR on discharge
Fig. 8
Fig. 8
Progression of illness as per WHO scores for each case
Fig. 9
Fig. 9
Trend of change in lab parameters with time

Similar articles

References

    1. World Health Organization Novel coronavirus (2019-nCoV) - situation report - 10 30. January 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/2...
    1. Khamis AH, Jaber M, Azar A, AlQahtani F, Bishawi K, Shanably A. Clinical and laboratory findings of COVID-19: A systematic review and meta-analysis. J Formos Med Assoc. 2021;120(9):1706–1718. doi: 10.1016/j.jfma.2020.12.003. - DOI - PMC - PubMed
    1. Chen G, Liao Q, Ai J, Yang B, Bai H, Chen J, Liu F, Cao Y, Liu H, Li K. Immune response to COVID-19 during pregnancy. Front Immunol. 2021;12:675476. doi: 10.3389/fimmu.2021.675476. - DOI - PMC - PubMed
    1. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, Debenham L, Llavall AC, Dixit A, Zhou D, Balaji R, Lee SI, Qiu X, Yuan M, Coomar D, Sheikh J, Lawson H, Ansari K, van Wely M, van Leeuwen E, Kostova E, Kunst H, Khalil A, Tiberi S, Brizuela V, Broutet N, Kara E, Kim CR, Thorson A, Oladapo OT, Mofenson L, Zamora J, Thangaratinam S, for PregCOV-19 Living Systematic Review Consortium Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. doi: 10.1136/bmj.m3320. - DOI - PMC - PubMed
    1. Garraud O, Heshmati F, Pozzetto B, Lefrere F, Girot R, Saillol A, Laperche S. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol. 2016;23(1):39–44. doi: 10.1016/j.tracli.2015.12.003. - DOI - PMC - PubMed